Registration is now open for MDMA’s 2021 FDA Forum (held virtually). Designed specifically for medical device regulatory professionals and executive decision makers, this conference will deliver key regulatory insights and preview trends that will impact your regulatory and business strategies.
CDRH Office of Product Evaluation and Quality (OPEQ) Director, William Maisel, is already confirmed for MDMA’s 2021 FDA Forum which will feature a number of senior officials from FDA and industry. This event will focus on the critical regulatory issues impacting the medical devices industry.
Topics will Include:
- FDA’s Response During COVID-19
- Navigating 510(k), De Novo & PMA Programs
- Digital Health
- CDRH Update
- Best Practices for Pre-submission Meetings
- Priorities from the New Administration
MDMA Members – $395
State Member – $495
Non-Members – $595